Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe

Key Points • Subsequent neoplasms observed in recipients of umbilical cord blood transplantation are rare, although associated with poor survival.• Determining risk factors and lifelong screening for early detection of subsequent neoplasms are mandatory to improve survival.

[1]  H. Trottier,et al.  Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis , 2021, Vaccines.

[2]  I. Shaheen,et al.  Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches. , 2020, World journal of transplantation.

[3]  J. Esteve,et al.  Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients , 2020, Bone Marrow Transplantation.

[4]  M. Labopin,et al.  Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients , 2019, JAMA oncology.

[5]  M. Labopin,et al.  European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation , 2018, Leukemia.

[6]  A. Shimoni,et al.  Second Malignancies after Hematopoietic Stem Cell Transplantation , 2018, Current Treatment Options in Oncology.

[7]  S. Yamasaki,et al.  Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma , 2017, Bone Marrow Transplantation.

[8]  P. Ljungman,et al.  Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines , 2016, Haematologica.

[9]  B. Shaw,et al.  Survival of patients who develop solid tumors following hematopoietic stem cell transplantation , 2015, Bone Marrow Transplantation.

[10]  M. Norkin,et al.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 , 2015, Bone Marrow Transplantation.

[11]  M. Sorror,et al.  Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  P. Amrolia,et al.  Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. , 2014, Blood.

[13]  E. Mayordomo,et al.  EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases , 2014, Bone Marrow Transplantation.

[14]  K. Kawa,et al.  Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Ljungman,et al.  Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation , 2014, Haematologica.

[16]  M. Shiseki,et al.  Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source , 2014, Bone Marrow Transplantation.

[17]  J. Armitage,et al.  Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients , 2013, Cancer biology & therapy.

[18]  H. Einsele,et al.  Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Robin,et al.  Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study , 2013, Bone Marrow Transplantation.

[20]  A. Nagler,et al.  Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced , 2013, Leukemia.

[21]  S. Stevanović,et al.  Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Stephanie J. Lee,et al.  Delivering care to long-term adult survivors of hematopoietic cell transplantation. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Moritake,et al.  Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan , 2012, International Journal of Hematology.

[24]  A. Tichelli,et al.  Late effects after hematopoietic stem cell transplantation--critical issues. , 2012, Current problems in dermatology.

[25]  P. Chevallier,et al.  Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation , 2012, Bone Marrow Transplantation.

[26]  N. Majhail.  Secondary cancers following allogeneic haematopoietic cell transplantation in adults , 2011, British journal of haematology.

[27]  S. Bhatia.  Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up , 2011, Expert review of hematology.

[28]  D. Wiseman.  Donor cell leukemia: a review. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  J. Wingard,et al.  Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. , 2010, Blood.

[30]  B. Yeap,et al.  Donor-derived second hematologic malignancies after cord blood transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  J. Wagner,et al.  Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  C. Haferlach,et al.  Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT , 2009, Bone Marrow Transplantation.

[33]  M. Kaminski,et al.  Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Jaffe,et al.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[35]  S. Asano,et al.  Donor cell-derived myelodysplastic syndrome after cord blood transplantation , 2009, Bone Marrow Transplantation.

[36]  Chung-Wu Lin,et al.  Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute , 2009, Bone Marrow Transplantation.

[37]  H. Deeg,et al.  Solid cancers after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[38]  J. Snowden,et al.  Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome/AML: failure of a lasting response to a second allogeneic transplant from the original donor , 2008, Bone Marrow Transplantation.

[39]  A. Zander,et al.  EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT , 2008, Bone Marrow Transplantation.

[40]  N. Majhail.  Old and new cancers after hematopoietic-cell transplantation. , 2008, Hematology. American Society of Hematology. Education Program.

[41]  J. Wagner,et al.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. , 2007, Blood.

[42]  S. Bhatia,et al.  Second malignancies after allogeneic hematopoietic cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[43]  P. Armand,et al.  Allogeneic stem cell transplantation for aplastic anemia. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  J. Mary,et al.  Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). , 2007, Blood.

[45]  D. Kaufman,et al.  Donor cell leukemia: insight into cancer stem cells and the stem cell niche. , 2007, Blood.

[46]  S. Asano,et al.  Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. , 2007, Blood.

[47]  B. Yeap,et al.  Double unrelated reduced-intensity umbilical cord blood transplantation in adults. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  Geneviève Gallagher,et al.  Second solid cancers after allogeneic hematopoietic stem cell transplantation , 2007, Cancer.

[49]  J. Wagner,et al.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. , 2006, Blood.

[50]  M. Greaves.  Cord blood donor cell leukemia in recipients , 2006, Leukemia.

[51]  J. Radich,et al.  Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[52]  Y. Tanizawa,et al.  Donor cell-derived acute myeloid leukemia after unrelated umbilical cord blood transplantation , 2006, Leukemia.

[53]  M. Routbort,et al.  Posttransplant Lymphoproliferative Disorder After Umbilical Cord Blood Transplantation in Children , 2006, The American journal of surgical pathology.

[54]  J. Wagner,et al.  First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. , 2005, Blood.

[55]  Y. Kodera,et al.  Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis , 2005, Bone Marrow Transplantation.

[56]  N. Schmitz,et al.  Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). , 2005, Haematologica.

[57]  L. Robison,et al.  New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Neugut,et al.  Therapy-Related Secondary Cancers , 2003 .

[59]  D. Hammerschmidt,et al.  Leukemia in donor cells after allogeneic hematopoietic stem cell transplant , 2002, Bone Marrow Transplantation.

[60]  J. Gribben,et al.  Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[61]  E. Jaffe,et al.  Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[63]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[64]  Barclay Ness,et al.  Royal Hospital for Sick Children , 1947, Glasgow medical journal.